Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis
Pfizer Inc. (NYSE:PFE) and Eli...
Read MorePfizer Inc. (NYSE:PFE) and Eli...
Read MoreDigital healthcare platform MyHealthcare has...
Read MorePembrolizumab (Keytruda) has received approval from...
Read MoreThe World Health Organization (WHO)...
Read MoreNovotech, the award-winning Asia-Pacific CRO...
Read MoreRegular infusions of an antibody...
Read MoreFindings from CPhI’s bio league...
Read MoreAMO Pharma Limited ("AMO Pharma"),...
Read MoreCRISPR Therapeutics (Nasdaq: CRSP) and...
Read MoreGranules India announced that the...
Read More